A stalled chromatin regulatory network that mediates the oncogenic activity of Meningioma-1

NIH RePORTER · NIH · R01 · $416,556 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY High expression of the transcriptional co-activator Meningioma-1 (MN1) is common in AML, and associated with a poor prognosis. Forced expression of MN1 in murine hematopoietic progenitors induces an aggressive leukemia. We recently discovered that the primary interaction partner of MN1 is the BAF nucleosome- positioning complex. MN1 stabilizes BAF on chromatin. MN1 binding is associated with sustained active enhancer chromatin at enhancers regulating a hematopoietic stem/progenitor program. We hypothesize that MN1 stabilizes promoter-enhancer contacts at these sites through a BAF dependent mechanism. The goal of this project is to uncover the molecular mechanism of MN1-mediated leukemic transformation. A better understanding of how MN1 causes leukemia may identify opportunities for targeted therapies in a patient population who is failing conventional AML therapy.

Key facts

NIH application ID
10818372
Project number
5R01CA262260-03
Recipient
CHILDREN'S HOSP OF PHILADELPHIA
Principal Investigator
KATHRIN M BERNT
Activity code
R01
Funding institute
NIH
Fiscal year
2024
Award amount
$416,556
Award type
5
Project period
2022-04-01 → 2027-03-31